As a result, outsourcing has become a preferred business model in this domain, providing increased flexibility, reduced costs and timely launch of drugs. Further, to keep up with the evolving client requirements, several contract manufacturing organizations have upgraded their existing capabilities / facilities.
Request a free sample of the report
https://www.rootsanalysis.com/reports/299/request-sample.html
The USD 40 billion (by 2035) financial opportunity within the HPAPI and cytotoxic drug manufacturing market has been analyzed across the following segments:
- Type of Product
- Highly Potent Active Pharmaceutical Ingredient
- Highly Potent Finished Dosage Form
- Company Size
- Small
- Mid-sized
- Large
- Very Large
- Scale of Operation
- Preclinical
- Clinical
- Commercial
- Type of Molecule
- Small Molecules
- Biologics
- Type of Highly Potent Finished Dosage Form
- Injectables
- Oral Solids
- Creams
- Others
- Key Geographical Regions
- North America (US, Canada and Mexico)
- Europe (UK, Italy, Germany, France, Spain and Rest of Europe)
- Asia-Pacific (China, India and Rest of Asia-Pacific)
- Rest of the World
The HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022 – 2035 report features the following companies, which we identified to be key players in this domain:
- AbbVie
- Abzena
- Aenova
- Cambrex
- CARBOGEN AMCIS
- Catalent
- Hovione
- Intas Pharmaceuticals
- Lonza
- Pfizer CentreOne
- Piramal Pharma Solutions
- Scinopharm
- STA Pharmaceutical (a WuXi AppTec company)
- Syngene
- Teva API
Table of Contents
- Preface
- Executive Summary
- Introduction
- Market Landscape
- Company Competitiveness Analysis
- Company Profiles: HPAPI and Cytotoxic Drug Manufacturers in North
America
- Company Profiles: HPAPI And Cytotoxic Drug Manufacturers in Europe
- Company Profiles: HPAPI and Cytotoxic Drug Manufacturers in Asia-
Pacific and Rest of the World
- Partnerships and Collaborations
- Recent Expansions
- Capacity Analysis
- Regional Capability Assessment Analysis
- Make Versus Buy Decision Making Framework
- Market Sizing and Opportunity Analysis
- SWOT Analysis
- Case-in-point: Contract Manufacturing Of Antibody Drug Conjugates
- Concluding Remarks
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To view more details on this report, click on the link :
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
You may also be interested in the following titles:
Cell Therapy Manufacturing Market
You may also like to learn what our experts are sharing in Roots educational series:
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com